Association between cumulative cisplatin dose and reproductive and sexual functions in patients with malignant ovarian germ cell tumors treated with bleomycin, etoposide, and cisplatin therapy: a case series study

Table 1 Bleomycin, etoposide, and cisplatin (BEP) therapy and pregnancy status in fertility-preserved patients

	Age, y	Histology type/FIGO stage	BSA, m²	Cumulative doses, mg/m²			Treatment cycle	Resumption of menses, M	Marital status	Live births
	Age, y	Histology type/FIGO stage	BSA, m²	BLM	VP-16	CDDP	Treatment cycle	Resumption of menses, M	Marital status	Live births
1	22	Immature teratoma/Ic	1.53	75	900	225	3	3	Yes	1
2	25	Immature teratoma/Ic	1.37	25	900	225	3	5	Yes	1
3	25	Mixed germ cell tumor/IIIb	1.53	100	1,200	300	4	6	Yes	2
4	16	Dysgerminoma/IIIc	1.57	185	1,625	325	6	2	No	-
5	29	Yolk sac tumor/Ic	1.66	75	900	225	3	3	No	-
6	14	Yolk sac tumor/Ic	1.42	210	2,500	500	5	4	No	-
7	18	Immature teratoma/Ia	1.49	220	2,000	400	4	5	No	-
8	27	Yolk sac tumor/IIIc	1.38	220	2,000	400	4	5	Yes	-
9	15	Immature teratoma/Ia	1.39	220	2,000	400	4	7	No	-
10	10	Immature teratoma/IIIc	1.24	60	1,440	400	4	12	No	-
	20 (15–26)	-	1.5 (1.4–1.5)	143 (71–220)	1,533 (900–2,000)	363 (225–400)	4 (3–4)	5 (3–6)	-	-

Continuous data are expressed as median (interquartile range)
Live births are expressed as the number after BEP therapy
Patient No. 10 received a total of 1 cycle of vinblastine, actinomycin D, and cyclophosphamide therapy following BEP therapy. Patient No. 8 had a history of pregnancy before BEP therapy, and she had no desire for additional childbearing after 4 cycles of BEP therapy
y Year, M Months, BSA Body surface area, FIGO International Federation of Gynecology and Obstetrics, BLM Bleomycin, VP-16 Etoposide, CDDP Cisplatin

ISSN: 2055-0294